{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:17Z","timestamp":1787026577727,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>High-dose interleukin-2 (HD IL-2) has curative potential in metastatic melanoma (MM) and renal cell carcinoma (RCC). Radiotherapy (RT) kills cancer cells and induces immunomodulatory effects. Prospective trials exploring clinical and immunological properties of combined RT\/HD IL-2 are still needed. We designed a phase II, single-arm clinical trial for patients with MM and RCC. The treatment schedule consisted of 3 daily doses of 6-12 Gy of RT to 1-5 non-index metastatic fields, before IL-2 at the first and third treatment cycle. HD IL-2 was administered by continuous infusion for 72 hours and repeated every 3 weeks for up to 4 cycles, thereafter every 4 weeks for a maximum of 2 cycles. The primary endpoint was the immunological efficacy of the combined RT\/HD IL-2 treatment (assessed by IFN-\u03b3 ELISPOT). Nineteen out of 22 patients were evaluable for immunological and clinical response. Partial response occurred in 3 (15.7%) patients and stable disease was observed in 7 (36.8%). The disease control rate was 52.6% after a median follow up of 39.2 months. According to Common Terminology Criteria for Adverse Events 4.0 (CTCAE 4.0), the majority of toxicities were grade 1-2. Immunological responses were frequent and detected in 16 (84.2%) patients. Increased levels of IL-8 and IL-10 in melanoma, circulating effector memory CD4+ and intratumoral CD8+ T cells in both tumor types were detected after therapy. Overall the treatment was well tolerated and immunologically active. Immunomonitoring and correlative data on tumor and peripheral blood cell subsets suggest that this combination treatment could be a promising strategy for patients progressing after standard treatments.<\/jats:p>","DOI":"10.3389\/fimmu.2021.778459","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T01:46:17Z","timestamp":1635299177000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Jenny","family":"Bulgarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Piccinini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Petracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pancisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Granato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"de Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Guidoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ancarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tontini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gentili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Valmorri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ferroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Crudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199809000-00004","article-title":"Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2: Identification of the Antigens Mediating Response","volume":"228","author":"Rosenberg","year":"1998","journal-title":"Ann Surg"},{"key":"B2","article-title":"Long-Term Survival Update for High-Dose Recombinant Interleukin-2 in Patients With Renal Cell Carcinoma","volume":"6","author":"Fisher","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"B3","article-title":"High-Dose Recombinant Interleukin-2 Therapy in Patients With Metastatic Melanoma: Long-Term Survival Update","volume":"6","author":"Atkins","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/1756287213505672","article-title":"Recent Developments in the Treatment of Renal Cell Carcinoma","volume":"5","author":"Dutcher","year":"2013","journal-title":"Ther Adv Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) Plus Nivolumab in Patients With Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e000673","DOI":"10.1136\/jitc-2020-000673","article-title":"ALKS 4230: A Novel Engineered IL-2 Fusion Protein With an Improved Cellular Selectivity Profile for Cancer Immunotherapy","volume":"8","author":"Lopes","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.7401099","article-title":"Interleukin 2: From Immunostimulation to Immunoregulation and Back Again","volume":"8","author":"Bachmann","year":"2007","journal-title":"EMBO Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6830","article-title":"Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma","volume":"24","author":"Cesana","year":"2006","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The Biology of Interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of Treatment of 255 Patients With Metastatic Renal Cell Carcinoma Who Received High-Dose Recombinant Interleukin-2 Therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200107000-00004","article-title":"Guidelines for the Safe Administration of High-Dose Interleukin-2","volume":"24","author":"Schwartzentruber","year":"2001","journal-title":"J Immunother"},{"key":"B12","article-title":"Clinical Pathways for Managing Patients Receiving Interleukin 2","volume":"5","author":"Mavroukakis","year":"2001","journal-title":"Clin J Oncol Nurs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-13","article-title":"Durable Responses and Reversible Toxicity of High-Dose Interleukin-2 Treatment of Melanoma and Renal Cancer in a Community Hospital Biotherapy Program","volume":"2","author":"Payne","year":"2014","journal-title":"J\u00a0Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt-2017-0082","article-title":"Radiation Therapy and Immunotherapy: What is the Optimal Timing or Sequencing","volume":"10","author":"Aliru","year":"2018","journal-title":"Immunotherapy"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/1084978041424972","article-title":"Repeated Cycles With 72-Hour Continuous Infusion Interleukin-2 in Kidney Cancer and Melanoma","volume":"19","author":"Quan","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2018\/e557s","article-title":"Radiotherapy and Immune Response: The Systemic Effects of a Local Treatment","volume":"73","author":"Carvalho","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7012","DOI":"10.1038\/s41598-018-25482-w","article-title":"Tumor Cure by Radiation Therapy and Checkpoint Inhibitors Depends on Pre-Existing Immunity","volume":"8","author":"Crittenden","year":"2018","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030457","article-title":"Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery","volume":"13","author":"Romano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12658","article-title":"Radiotherapy-Immunotherapy Combinations - Perspectives and Challenges","volume":"14","author":"Mondini","year":"2020","journal-title":"Mol Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy With High-Dose Interleukin-2 (HD IL-2) in Metastatic Melanoma and Renal Cell Carcinoma Following PD1 or PDL1 Inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200005000-00001","article-title":"Quantification of Tumor-Specific T Lymphocytes With the ELISPOT Assay","volume":"23","author":"Schmittel","year":"2000","journal-title":"J Immunother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/erv.10.169","article-title":"ELISpot for Measuring Human Immune Responses to Vaccines","volume":"10","author":"Slota","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-2-9","article-title":"A Modified Human ELISPOT Assay to Detect Specific Responses to Primary Tumor Cell Targets","volume":"2","author":"Malyguine","year":"2004","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2013.802802","article-title":"Carbon Anhydrase IX Specific Immune Responses in Patients With Metastatic Renal Cell Carcinoma Potentially Cured by Interleukin-2 Based Immunotherapy","volume":"35","author":"Rasmussen","year":"2013","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0668","article-title":"Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered With Interleukin 2: A Phase II Trial","volume":"14","author":"Amato","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1520","article-title":"The High-Dose Aldesleukin \"Select\" Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients With Metastatic Renal Cell Carcinoma","volume":"21","author":"McDermott","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.06.012","article-title":"Durable Benefit and the Potential for Long-Term Survival With Immunotherapy in Advanced Melanoma","volume":"40","author":"McDermott","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B28","article-title":"High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma and Metastatic Melanoma: Still the Standard","volume":"25","author":"Dutcher","year":"2011","journal-title":"Oncol (Williston Park)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0262-6","article-title":"Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-Dose Interleukin-2: Evaluation of Biomarkers of Immunologic and Therapeutic Response","volume":"12","author":"Ridolfi","year":"2014","journal-title":"J Transl Med"},{"key":"B30","first-page":"43","article-title":"Designs for Efficient Clinical Trials","volume":"3","author":"Simon","year":"1989","journal-title":"Oncol (Williston Park)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000177999.95831.7b","article-title":"Glucocorticoids do Not Inhibit Antitumor Activity of Activated CD8+ T Cells","volume":"28","author":"Hinrichs","year":"2005","journal-title":"J Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31823735d6","article-title":"Ipilimumab in Treatment-Naive and Previously Treated Patients With Metastatic Melanoma: Retrospective Analysis of Efficacy and Safety Data From a Phase II Trial","volume":"35","author":"Thompson","year":"2012","journal-title":"J Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189","article-title":"Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/1758835921996656","article-title":"Impact of the Corticosteroid Indication and Administration Route on Overall Survival and the Tumor Response After Immune Checkpoint Inhibitor Initiation","volume":"13","author":"Gaucher","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02353","article-title":"Dendritic Cell Vaccination in Metastatic Melanoma Turns \"Non-T Cell Inflamed\" Into \"T-Cell Inflamed\" Tumors","volume":"9","author":"Bulgarelli","year":"2019","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clgc.2016.10.008","article-title":"Impact of Sequencing Targeted Therapies With High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-Going Observational IL-2 Clinical Trial: PROCLAIMSM","volume":"15","author":"Clark","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1910-x","article-title":"Contemporary Experience With High-Dose Interleukin-2 Therapy and Impact on Survival in Patients With Metastatic Melanoma and Metastatic Renal Cell Carcinoma","volume":"65","author":"Alva","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2020-001650","article-title":"Long-Term Progression-Free Survival of Patients With Metastatic Melanoma or Renal Cell Carcinoma Following High-Dose Interleukin-2","volume":"69","author":"Clark","year":"2021","journal-title":"J Investig Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-018-0387-x","article-title":"A Multi-Center Phase II Study of High Dose Interleukin-2 Sequenced With Vemurafenib in Patients With BRAF-V600 Mutation Positive Metastatic Melanoma","volume":"6","author":"Clark","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01483","article-title":"High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma","volume":"9","author":"Silk","year":"2020","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e000773","DOI":"10.1136\/jitc-2020-000773","article-title":"Randomized Phase II Study of Stereotactic Body Radiotherapy and Interleukin-2 Versus Interleukin-2 in Patients With Metastatic Melanoma","volume":"8","author":"Curti","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bju.14461","article-title":"Safety and Efficacy of Nivolumab for Metastatic Renal Cell Carcinoma: Real-World Results From an Expanded Access Programme","volume":"123","author":"De Giorgi","year":"2019","journal-title":"BJU Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab After Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, Vemurafenib, and Cobimetinib as First-Line Treatment for Unresectable Advanced BRAF V600 Mutation-Positive Melanoma (IMspire150): Primary Analysis of the Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0054","article-title":"NCCN Guidelines Insights: Kidney Cancer, Version 2.2020","volume":"17","author":"Motzer","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in Combination With Stereotactic Body Radiotherapy in Pretreated Patients With Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study","author":"Masini","year":"2021","journal-title":"Eur Urol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.778459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T01:46:22Z","timestamp":1635299182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.778459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2021.778459"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.778459","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"article-number":"778459"}}